MEDICAL PROFESSIONALS

References

1. Go, AS et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm    management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA)  Study. JAMA (2001) 285: 2370-5.
2. Steinberg, JS et al. Atrial fibrillation: an emerging epidemic? Heart (2004) 90: 239-40.
3. Hogue, CW et al. Epidemiology, mechanisms, and risks: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. (2005) Chest 128: 9S-16S.
4. Wolf, PA et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. (1978) Neurology 28: 973-7.
5. Wolf, PA et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. (1991) Stroke 22: 983-8.
6. Krahn, AD et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. (1995) Am J Med 98: 476-84.
7. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. (1992) Ann Int Med 116: 1-5.
8. Le Heuzey, JY et al. Cost of care distribution in atrial fibrillation patients: the COCAfib study. (2004) Am Heart J 147:121-6.
9. Roy, D et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. (2000) N Engl J Med 342: 913-20.
10. Ehrlich, JR et al. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. (2006) Eur Heart J 27: 512-8.
11. Wijffels, MC et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. (1995) Circulation 92: 1954-68.
12. Tamargo, J et al. Pharmacological approaches in the treatment of atrial fibrillation. (2004) Curr Med Chem 11: 13-28.
13. Nattel S & Opie LH Controversies in atrial fibrillation. (2006) Lancet 367: 262-72.
14. Good ED & Oral H Curative catheter ablation for atrial fibrillation. (2005) Curr Treat Options Cardiovasc Med 7: 351-8.
15. Hocini, M et al. Techniques for curative treatment of atrial fibrillation. (2004) J Cardiovasc Electrophysiol 15: 1467-71.
16. Haïssaguerre, M et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. (1998) N Engl J Med 339: 659-66.
17. Oral, H et al. A tailored approach to catheter ablation of paroxysmal atrial fibrillation (2006) Circulation (in press).
18. Cappato, R et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. (2005) Circulation 111: 1100-5.
19. Oral, H et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. (2002) J Am Coll Cardiol 40: 100-4.
20. Pappone, C et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. (2003) J Am Coll Cardiol 42: 185-97.
21. Wazni, OM et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. (2005) JAMA 22. Stabile, G et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). (2006) Eur Heart J 27: 216-21.
23. Oral, H et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. (2006) N Engl J Med 354: 934-41.
24. Pappone, C et al. A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy for Curing Paroxysmal Atrial Fibrillation: The Ablation for Paroxysmal Atrial Fibrillation (APAfib) Trial (2006) American College of Cardiology, Late Breaking Clinical Trials, 55th Annual Scientific Session in Atlanta, March 11-14.
25. Katkhouda, N et al. Laparoscopic versus open appendectomy: a prospective randomized double-blind study. (2005) Ann Surg 242: 439-50.
26. Perrone, JM et al. Perioperative outcomes and complications of laparoscopic ventral hernia repair. (2005) Surgery 138: 708-15.
27. Schafer, M et al. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. (2002) Ann Surg 236: 137-48.
28. Harris, WJ Early complications of abdominal and vaginal hysterectomy. (1995) Obstet Gynecol Surv 50: 795-805.
29. Kulier, R et al. Minilaparotomy and endoscopic techniques for tubal sterilisation. (2002) Cochrane Database Syst Rev CD01328.
30. Verma A & Natale A. Should atrial fibrillation ablation be considered first-line therapy for some patients? Why atrial fibrillation ablation should be considered first-line therapy for some patients. (2005) Circulation 112: 1214-22.
31. Boston Symposium on Atrial Fibrillation (2006).
32. Weerasooriya, R et al. Cost analysis of catheter ablation for paroxysmal atrial fibrillation. (2003) Pacing Clin Electrophysiol 26: 292-4.
33. Goldberg, A et al. Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources. (2003) J Interv Card Electrophysiol 8: 59-64.

 

  • Email this page
©Johnson & Johnson Medical NV/SA, 2010. Last update on:06 Aug 2010 This site is published by Johnson & Johnson Medical NV/SA, which is solely responsible for its contents. This section of the website is intended for visitors from the European Economic Area (EEA), excluding France. The EEA includes the 25 EU member states and Norway, Iceland, and Liechtenstein. Capitalized product names are trademarks of Biosense Webster.